Skip to main content
. Author manuscript; available in PMC: 2024 Sep 1.
Published in final edited form as: J Allergy Clin Immunol. 2023 Apr 24;152(3):711–724.e14. doi: 10.1016/j.jaci.2023.04.007

Figure 5. Co-engagement of FcεRI and Siglec-9 inhibits mast cell degranulation, production of arachidonic acid metabolites, and IL-8 release.

Figure 5.

(A-F) LAMP-1 expression in PBCMCs (A) and HSCMCs (B), and reduction in LAMP-1 expression (C), cys-LT (D), PGD2 (E) and IL-8 production in PBCMCs and HSCMCs maintained in medium alone or incubated with either isotype control or mouse anti-Siglec-9 (5 μg/ml) and stimulated with anti-human FcεRIα (100 ng/ml) and a goat anti-mouse IgG (Fc specific) F(ab’)2 fragment antibody (5 μg/ml) to cross-link FcεRIα and Siglec-9. Data are shown as mean + SEM. Triangles in A (n = 6–7), C (n = 7), D (n = 4), E (n = 7) and F (n = 5), and squares in B (n = 3–4) C (n = 4), D (n = 4), E (n = 4) and F (n = 4), show values from individual experiments with cells generated from individual donors. In A and B: *P < 0.05, **P < 0.01, ****P <0.0001. In C-F: *P < 0.05, **P < 0.01, ***P <0.001 vs. cells treated with isotype control.